Polycystic Ovary Syndrome Drugs Market to Witness Incremental Dollar Opportunity

Posted by Bisvjeet on February 25th, 2019

Polycystic ovary disorder (PCOS) is a usual hormonal endocrine issue that influences women of baby bearing age that is 15 to 49 years. This ailment otherwise called as Stein-Leventhal Syndrome is described by the structure of cysts on the ovaries prompting an inadequacy of the ovulation setting off hormone in the female body. PCOS, for the most part, happens because of a mix of genetic and environmental variables that cause an abnormal role of the hormones there in the pituitary organ which manages ovulation. A couple of the symptoms of PCOS incorporate acne, infertility, body hair excess, facial, irregular menstruation and other skin problems. PCOS is moreover connected with diseases, for example, obesity2, diabetes, acute depression, obstructive sleep apnea and heart diseases. At present, there are no particular diagnostic tests accessible for the recognition of PCOS nevertheless medical history analysis, vaginal ultrasound, physical examination, and blood tests are widely suggested by general doctors and gynecologists.

Expansion of the overall market is chiefly fuelled by rising occurrence of the disease along with increasing awareness and adoption amid the patient populace. The worldwide market for polycystic ovary syndrome drugs is likely to record a CAGR of 4.7% over the projection period 2016–2024. The worldwide PCOS Drugs Market will be reaching a value of US$ 1,155 Million through 2024. Conversely, rising side effects related to generics and the need for FDA approved drugs may hinder market expansion all through the assessment period.

 Request For Report Sample: https://www.researchreportinsights.com/report/sample/110115019/Polycystic-Ovary-Syndrome-Drugs-Market 

The worldwide market for PCOS drugs is categorized on the basis of drug class into insulin-sensitizing agents, oral contraceptives, ornithine decarboxylase inhibitors, anti-depressants, diuretics and aromatase inhibitors. The contraceptive drug class category is estimated to record a 5.4% CAGR during the assessment period. The oral contraceptives are normally the chosen therapy for the treatment since they are easily obtainable as OTC medicines. The insulin-sensitizing agent category is estimated to record a 4.8% CAGR throughout the assessment period. The worldwide market for PCOS drugs is categorized on the basis of the distribution channel into fertility clinics, E-commerce, drug stores/OTC and hospital pharmacies. The hospital pharmacies category will be leading the worldwide market for PCOS drugs in revenue terms and is expected to account for a value of about US$ 576 Million by 2024 end. The drugs stores/OTC category was expected to account for 27% of the worldwide market share in valuation terms towards 2016 end.

Geographically, the North American region was considered to remain dominant among other regions and with the highest value share of the worldwide market by 2016 end. The Asia Pacific region is projected to account for the maximum 5.6% CAGR throughout the predicted period. 

Some of the major players manufacturing in the worldwide market include Novartis AG, Sanofi, Addex Therapeutics Ltd., Teva Pharmaceutical Industries Limited, Merck KGaA, BIOCAD, Bristol Myers Squibb Co., AstraZeneca plc., Crinetics Pharmaceuticals, Inc and Ferring Pharmaceuticals, Inc.


Like it? Share it!


About the Author

Joined: March 7th, 2018
Articles Posted: 947

More by this author